Furthermore, the long-term effects of the presence of these IL-17A producing cells in TNBC following DOX treatment will require further analysis to establish therapeutic efficacy as studies on the effects of IL-17 in tumor development and progression have been controversial (20, 21, 73) and outcomes may be dependent on tumor subtypes and stage of the disease. The gene discussed is IL17A; the disease is neoplasm.